| Literature DB >> 23631805 |
Carmen Petronzi1, Michela Festa, Antonella Peduto, Maria Castellano, Jessica Marinello, Antonio Massa, Anna Capasso, Giovanni Capranico, Annalisa La Gatta, Mario De Rosa, Michele Caraglia, Rosanna Filosa.
Abstract
BACKGROUND: Tumors are diseases characterized by uncontrolled cell growth and, in spite of the progress of medicine over the years, continue to represent a major threat to the health, requiring new therapies. Several synthetic compounds, such as those derived from natural sources, have been identified as anticancer drugs; among these compounds quinone represent the second largest class of anticancer agents in use. Several studies have shown that these act on tumor cells through several mechanisms. An important objective of this work is to develop quinoidscompounds showing antitumor activity, but with fewer side effects. The parachinone cannabinol HU-331, is a small molecule that with its core 4-hydroxy-1,4-benzoquinone, exhibits a potent and selective cytotoxic activity on different tumor cell lines. A series of derivatives 3-hydroxy-1,4-benzochinoni were thus developed through HU-331 chemical modifications. The purpose of the work is to test the ability of the compounds to induce proliferative inhibition and study the mechanisms of cell death.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23631805 PMCID: PMC3666920 DOI: 10.1186/1756-9966-32-24
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN: 0392-9078
Figure 1Development of compounds of general formula A and B.
Oxidation of 4-Hexylresorcinol to V with different oxidizing agents
| Salcomine (0.01 eq.) ,DMF, 110°C, 3 h | 30a | |
| Salcomine (1 eq.), DMF, rt, 6 h | 50a | |
| Etanol/air, Petroleum ether, KOH 5%, 0°C, 5 h | 33 | |
| Fremy’s salt, Aliquat336/Ph, Na2CO3, rt, 18 h | 30a | |
| Fremy’s salt, H2O, Na2HPO4, rt to 50°C, 36 h | 22 | |
| Fremy’s salt, H2O/EtOAc, Na2HPO4, 0°C to rt, 18 h | 50 | |
| Fremy’s salt, H2O/THF, Na2CO3,rt, 10 h | 60 |
aConversion of starting material in o-hydroxyquinone.
Effects of HU compounds on proliferation of several cancer cell lines
| H | H | H | >100 | >100 | >100 | >100 | >100 | ||
| n-hexyl | H | H | 23 ± 0.12 | 28.13 ± 0.07 | 41 ± 0.20 | 34.91 ± 3.82 | >100 | ||
| H | H | H | >100 | >100 | >100 | >100 | >100 | ||
| n-hexyl | H | H | 45.6 ± 0.20 | 37.3 ± 0.34 | 38 ± 0.12 | 30.7 ± 0.12 | |||
| n-hexyl | H | H | H | ||||||
| H | n-hexyl | H | H | - | >100 | >100 | >100 | >100 | |
| H | n-hexyl | CH3 | H | - | >100 | >100 | >100 | >100 | |
| H | H | CH3 | n-hexyl | - | >100 | >100 | >100 | >100 | |
| -CH3 | n-butyl | CH3 | H | 24.5 ± 0.15 | 51 ± 0.02 | ||||
| H | n-butyl | CH3 | H | 35 ± 0.64 | >100 | >100 | >100 | >100 | |
| H | n-butyl | H | H | >100 | >100 | >100 | >100 | >100 | |
| -CH3 | n-hexyl | CH3 | H | >100 | |||||
| H | n-hexyl | CH3 | H | >100 | |||||
| H | n-hexyl | H | H | >100 | >100 | >100 | >100 | >100 | |
| 15.0 ± 0.09 | 24.5 ± 0.15 | 32.0 ± 0.15 | 34.6 ± 0.23 | 21.8 ± 0.03 | |||||
Cell viability was assessed through MTT assay. Data represent the mean ± SD values of three independent determinations performed in triplicate. , , human melanoma cells; , human breast cancer cells; , Human prostate cancer cell line, , Human renal cancer cell line.
Cytotoxic activity of compound V in solid human cancer cell lines
| Prostate | LN-CAP | |
| DU-145 | ||
| Pancreas | BX-PC3 | |
| PANC-1 | 31.6 | |
| Renal | SN12C | 23.6 |
| RXF393 | ||
| 769P | 34.6 | |
| Glioblastoma | LN229 | |
| U373MG | 23.6 | |
| U87MG | 30.8 | |
| Breast | CG-5 | 34.6 |
| | MDA-MB 231 | 33.6 |
| | MDA-MB 468 | 41.2 |
| MDA-MB 436 | 40.1 | |
Figure 2Dose–response curves from the treatment of different cell lines with the molecule HU-100-V with an IC50 between more less than 20 μM.
Figure 3Effects of HU compounds on apoptosis of human melanoma M14 cells. Analysis of the % of apoptotic cells was performed using PI cell permeabilization staining. M14 cells were treated with different concentrations of HU-331 and V (1–10 μM) for 24–72 h. Cells were then collected and % of hypodiploid nuclei was analyzed by flow cytometry (*** P < 0.001 vs 72 h control cells; ° P < 0.05, °°° P < 0.001 vs 24 h control cells). Results are expressed as mean ± SEM of three experiments performed in triplicate.
Figure 4Effects of the caspase inhibitor Z-VAD-FMK on apoptosis induced by HU331 and V in human melanoma M14 cells. Z-VAD-FMK (30 μM) was administered 30 min before incubation with HU-331 and V (10 μM) for 72 h and the % of apoptotic cell was evaluated by flow cytometry (mean ± SEM of three experiment performed in triplicate; ***P < 0.001 vs control cells, §§§ P < 0.001 HU331 vs V treated cells.
Figure 5Effect of HU compounds on intracellular ROS generation at early time points in M14 cells. Cells were treated with V and HU331 for 30 min and then intensity of fluorescence of positive cells to DCFH-DA was analyzed by flow cytometry (FL-1channel). Results are representative of three experiments performed in triplicate. MFI:mean fluorescence intensity.
Figure 6Western blotting analysis of PARP cleavage and XIAP protein expression after incubation with HU-331 and V(10 μM) for 24 hours. Blots are representative of three different experiments.